期刊文献+

比马前列素治疗青光眼不良反应临床分析

Clinical Analysis of Adverse Reactions of Bimatoprost Treatment for Glaucoma
下载PDF
导出
摘要 目的研究张家口地区青光眼患者应用比马前列素治疗后的不良反应情况及患者对不良反应的态度,以指导临床合理用药。方法选择2012年2月至2012年6月于张家口市第四医院进行治疗的48例青光眼患者作为研究对象,在应用比马前列素治疗前和6个月后观察眼睑、虹膜色素沉着程度,并对睫毛增长及硬度情况和眼睑毫毛状态进行评估。同时通过调查问卷形式评价患者关于不良反应主观判断情况。结果应用比马前列素治疗后有77.1%的患者出现不良反应情况,其中有22例出现睫毛长长,25例睫毛变硬,19例眼睑毫毛增加,3例眼睑色素沉积,24例虹膜色素沉积。不良反应出现情况的主、客观评价结果除眼睑色素沉积与虹膜色素沉积存在差异外(P<0.05),其他基本一致。结论大多数患者能够意识到不良反应的发生。在使用比马前列素进行治疗前需要对患者进行充分的解释,进行治疗时也应及时进行细致地监测以减少不良发应的损害。 Objective To prospectively investigate adverse reactions of bimatoprost treatment for glauco- ma in Zhangjiakou area, and examine patient attitudes to the adverse reactions to guide the rational medica- tion in clinical. Methods A total of 48 patients with glaucoma from Feb. 2012 to Jun. 2012 from Zhangjiak- ou Fourth Hospital were enrolled. Eyelid pigmentation, iridial pigmentation, eyelash growth and bristle, and vellus hair of the lid before medication and six months after medication were observed and assessed. Question- naires completed by patients provided insight into their subjective judgment of adverse reactions. Results After bimatoprost treatment 77.1% patients had adverse reaction, including 22 eases of eyelash growth, 25 cases of eyelash bristle,19 cases of vellus hair of the lid,3 cases of eyelid pigmentation and 24 cases of iris pigmentation. The objective and subjective assessments were in agreement in terms of increase in eyelash bristle, eyelash growth, and increase in vellus hair of the lid, while there were significant differences ( P 〈 0.05 ) in eyelid pigmentation and iris pigmentation. Conclusion Most patients were conscious of these adverse reactions. Before treatment, sufficient explanation of potential adverse reactions should be provided, and care- ful observation is required after initiating the treatment.
出处 《医学综述》 2014年第2期369-370,共2页 Medical Recapitulate
关键词 比马前列素 不良反应 眼睑色素沉积 眼睫毛改变 虹膜色素沉积 Bimatoprost Adverse reaction Eyelid pigmentation Changes in eyelashes Iris pigmentation
  • 相关文献

参考文献8

  • 1Khidhir KG,Woodward DF, Farjo NP, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias[ J]. FASEB J ,2013,27 ( 2 ) :557-567. K.
  • 2im YT, Moon SK, Maruyama T, et al. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity[ J]. Neu- robiol Dis,2012,48( 1 ) :58-65.
  • 3Nixon DR, Simonyi S, Bhogal M, et al. An observational study of bimatoprostO. 01% in treatment-na? ve patients with primary open angle glaucoma or ocular hypertension : the CLEAR trial [ J ]. Clin Ophthalmol, 2012,6 : 2097 -2103.
  • 4Ichhpujani P,Katz LJ, Hollo G, et al. Comparison of human ocular distribution of bimatoprost and latanoprost [ J ]. J Ocul Pharmacol Ther ,2012,28 ( 2 ) : 134-145.
  • 5Choi HY,Lee JE, Lee JW,et al. In vitro study of antiadipogenic pro- file of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes [ J ]. J Ocul Pharmacol Ther, 2012,28 ( 2 ) : 146-152.
  • 6Guedes RA, Guedes VM, Freitas SM, et al. Quality of life of glauco- ma patients under medical therapy with different prostaglandins[ J]. Clin Ophthalmo1,2012,6 : 1749-1753.
  • 7Lee CW, Buckley F, Costello S, et al. A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma [ J ]. Curr Med Res Opin, 2008,24 ( 8 ) :2265-2270.
  • 8Scherzer ML, Liehneova I, Negrete FJ,et al. Travoprost O. 004%/ timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03 %/timolol 0.5 % [ J ]. Adv Ther, 2011, 2R ( 8 ):661-670.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部